English
Services
Service inquiries:
| No. | Work / service | Unit price, RUB |
|---|---|---|
| 1 | Provision and analysis of collection samples | negotiable |
| 2 | Expansion of cell lines | negotiable |
| 3 | Selection (collection) of clinical samples according to the customer's parameters | negotiable |
| 4 | Characterization of samples by genetic methods (PCR, STR profiling, sequencing) and immunochemical methods | negotiable |
| 5 | Study of specific activity in vitro on cell models and in vivo on animal models, including human tumor xenografts | negotiable |
| 6 | Molecular studies | negotiable |
| 7 | Study of the pharmacokinetics and biodistribution of drugs | negotiable |
| 8 | Drug safety studies | negotiable |
| 9 | Generation of hybridomas to the customer's antigens | negotiable |
| 10 | Production, purification, characterization, and modification of antibodies | negotiable |
| 11 | Training under the program "Fundamentals of Working with Cell Lines" (basic) | negotiable |
| 12 | Training under the program "Characterization of Human Cell Lines" (advanced) | negotiable |
| No. | Work / service | Unit price, RUB |
|---|---|---|
| 13 | Expansion of human and animal tumor cell lines | negotiable |
| 14 | Generation of new human tumor cell lines | negotiable |
| 15 | In vitro study of drug cytotoxicity using the MTT assay | negotiable |
| 16 | Studies using the BD FACS Canto II flow cytometer: | negotiable |
| 17 | Study of cell death (caspases, annexin V and propidium iodide staining) | negotiable |
| 18 | Study of the cytokine profile (CBA) | negotiable |
| 19 | Assessment of the immunophenotype of human blood cells | negotiable |
| 20 | Assessment of the immunophenotype of tumor cells | negotiable |
| 21 | Assessment of the immunophenotype of mouse spleen cells | negotiable |
| 22 | ELISA | negotiable |
| 23 | ELISPOT | negotiable |
| 24 | Generation of cytotoxic T lymphocytes | negotiable |
| 25 | Preparation of dendritic cell vaccines | negotiable |
| 26 | Isolation and cryopreservation of peripheral blood mononuclear cells | negotiable |
| 27 | Storage of biosamples in liquid nitrogen | negotiable |
Laboratory of Immunopharmacology
| No. | Work / service | Unit | Unit price, RUB | Notes |
|---|---|---|---|---|
| 28 | Biological method for in vitro analysis of adaptogens using baker's yeast Saccharomyces cells | Total adaptogenicity score | not yet clearly defined | The biological method for in vitro analysis of adaptogens using baker's yeast Saccharomyces cerevisiae cells can be used for the qualitative and quantitative identification of both individual and complex phytoadaptogens. It allows detection of adulterations. The total adaptogenicity score (TAS) is unique to each adaptogen and distinguishes it from any other adaptogen. |
| No. | Work / service | Unit price, RUB |
|---|---|---|
| 29 | Development of a method and determination of the specific activity of monoclonal antibodies or chemical substances on cell cultures | negotiable |
| 30 | Study of the cytotoxic activity of monoclonal antibody preparations | negotiable |
| 31 | Confirmation of the biosimilarity of monoclonal antibody preparations | negotiable |
| 32 | Study of the binding of monoclonal antibody preparations to the target antigen | negotiable |
| 33 | Study of the binding of monoclonal antibody preparations to Fc-gamma receptors (FcγRI, FcγRII, FcγRIII) and complement (C1q) | negotiable |
| 34 | Study of the binding of Fab-associated functions of monoclonal antibody preparations | negotiable |
| 35 | Study of the induction of complement-dependent cytotoxicity by monoclonal antibody preparations | negotiable |
| 36 | Study of the induction of antibody-dependent cellular cytotoxicity by monoclonal antibody preparations | negotiable |
| 37 | Study of apoptosis induction in cell cultures | negotiable |
| 38 | Study of specific activity on tissue explants | negotiable |
| 39 | Study of specific antiangiogenic activity by the endothelial cell tube formation assay | negotiable |
| 40 | Study of specific antiangiogenic activity on human endothelial cells | negotiable |
| 41 | Study of the cross-reactivity of monoclonal antibody preparations on a tissue panel | negotiable |
| 42 | Study of the expression of molecular markers by immunohistochemical staining | from 3500/marker |
| 43 | Study of the expression of molecular markers by flow cytometry | from 2500/marker |
| 44 | Immunofluorescent staining and microscopy of cellular markers | from 2500/marker |
| 45 | Generation of three-dimensional cell spheroids for screening the specific activity of monoclonal antibodies or chemical substances | negotiable |
| No. | Work / service | Unit price, RUB |
|---|---|---|
| 46 | development of technologies for producing both generic and innovative antitumor drugs: development of the composition and manufacturing technology of dosage forms for hydrophobic and hydrophilic active pharmaceutical ingredients (APIs), selection of API delivery systems in order to create more effective and safer drugs | negotiable |
| 47 | development of prolonged-release liquid (suspensions, solutions), solid (tablets, capsules, solid dispersions), and lyophilized dosage forms for oral and parenteral administration based on nanotechnology using universal polymer complexes, nanoparticles, nanosized micellar and liposomal dosage forms that make it possible to increase the bioavailability, efficacy, quality, and safety of new drugs | negotiable |
| 48 | production of pilot-industrial batches of drugs for preclinical studies, including lyophilized ones, with quality control | negotiable |
| 49 | development and validation of analytical and technological methods used at all stages of production technology development and for quality control of drugs and APIs | negotiable |
| 50 | scaling up of drug production technologies for application in industrial manufacturing | negotiable |
| 51 | studies on the stability and shelf life of drugs, including stress testing in the accelerated aging test | negotiable |
| 52 | development of regulatory documentation (laboratory and industrial regulations, specifications) | negotiable |
| 53 | development of a marketing authorization dossier for a drug (ICH, Recommendation of the Board of the Eurasian Economic Commission of October 8, 2019 No. 29 "On Methodological Recommendations on the Content and Structure of Documents of the Registration Dossier of a Medical Device", GCP) | negotiable |
| 54 | development of a drug preclinical study protocol, organization and control of the entire complex of preclinical studies (GOST R 56701-2015 "Medicines for medical use. Guidelines for planning preclinical safety studies for the purpose of subsequent clinical trials and drug registration", ICH M3(R2):2009 "Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals")" | negotiable |
| No. | Work / service | Unit price, RUB |
|---|---|---|
| 55 | Assessment of the cytotoxic effect of new agents on cell models (primary cell cultures, collection cell cultures) | negotiable |
| 56 | Assessment of the antiproliferative effect on spheroid models | negotiable |
| 57 | Generation of primary tumor cell cultures | negotiable |
| 58 | Generation of primary tumor xenografts in immunodeficient Balb/c nude mice | negotiable |
| 59 | Assessment of the tumorigenicity of cell cultures in immunodeficient Balb/c nude mice | negotiable |
| 60 | Assessment of the antitumor activity of new agents in human tumor xenograft models in immunodeficient Balb/c nude mice | negotiable |
| 61 | Assessment of the antitumor activity of new agents in human tumor xenograft models in Danio rerio embryos | negotiable |
| 62 | Assessment of the antitumor activity of new agents in syngeneic mouse and rat tumor models | negotiable |
| 63 | In-depth assessment of antitumor activity (combined use of drugs, characterization of the therapeutic dose range, assessment of the effect under tolerability monitoring) | negotiable |
| 64 | Assessment of the antimetastatic potential of agents | negotiable |
| No. | Work / service | Unit price, RUB |
|---|---|---|
| 65 | acute toxicity in rodents (mice, rats, guinea pigs, rabbits) and non-rodents (dogs) | negotiable |
| 66 | subacute, subchronic, and chronic toxicity in rodents (mice, rats, guinea pigs, rabbits) and non-rodents (dogs) | negotiable |
| 67 | cumulative effect in rodents (mice, rats, guinea pigs, rabbits) and non-rodents (dogs) | negotiable |
| 68 | local irritant effect (in mice, rats, guinea pigs, rabbits, dogs) | negotiable |
| 69 | allergenicity (guinea pigs, mice, rats) | negotiable |
| 70 | teratogenicity (rats, rabbits) | negotiable |
| 71 | embryotoxicity (rats, rabbits) | negotiable |
| 72 | gonadotoxicity (rats, rabbits) | negotiable |
| 73 | pyrogenicity (rabbits, LAL) | negotiable |
| 74 | pathomorphology (histotoxicology, oncomorphology, forensic veterinary examination) | negotiable |
| 75 | determination of species sensitivity in rodents (mice, rats, guinea pigs, rabbits) and non-rodents (dogs) | negotiable |
| 76 | calculation of the starting dose for phase I of clinical studies | negotiable |
| 77 | antidote therapy | negotiable |
| 78 | assessment of specific types of toxicity (neurotoxicity, cardiotoxicity, nephrotoxicity, etc.) | negotiable |
| 79 | pharmacological compatibility and drug interactions (mice, rats, guinea pigs) | negotiable |
| 80 | biological quality control of drugs for toxicity (mice, guinea pigs) and pyrogenicity (rabbits) | negotiable |
| 81 | laboratory tests in all animal species | negotiable |
| 82 | preclinical safety studies of suture material, medical devices, new methods of drug use, as well as new methods of treating patients using surgical operations (rats, dogs). | negotiable |
| 83 | pharmacokinetic studies of new antitumor drugs at the preclinical stage and in the first phases of clinical trials | negotiable |
| 84 | development of methods for the quantitative determination of drugs in biological fluids and tissues | negotiable |
| 85 | study of the absorption, distribution, excretion, and metabolism of antitumor drugs | negotiable |
| 86 | mathematical modeling of pharmacokinetic processes | negotiable |
| 87 | comprehensive study of the absolute, relative, and specific bioavailability of drugs in various dosage forms | negotiable |
| 88 | training in methods of working with laboratory animals in biological and medical research | negotiable |
| 89 | training in methods of experimental morphology | negotiable |
| No. | Work / service | Unit price, RUB |
|---|---|---|
| 90 | In vivo screening of cytotoxically active compounds from different chemical classes to assess their antitumor activity | negotiable |
| 91 | In-depth study of the specific antitumor activity of new antitumor agents among chemical compounds of different classes in transplantable mouse and rat tumors | negotiable |
| 92 | Preclinical studies of new antitumor agents among chemical compounds of different classes in transplantable mouse and rat tumors, including: — determination of the therapeutic dose range with proof of the selectivity of the therapeutic action (therapeutic index); — study of the effect on an established tumor; — selection of the optimal route of administration; — selection of the optimal dosing regimen; — comparative study of the efficacy of the substance and the dosage form; — study of the mechanism of antitumor action aimed at specific cellular targets. Additional studies: — study of efficacy in combination with known antitumor drugs; — study of the effect on a tumor with acquired drug resistance; — study of the ability to inhibit the metastasis of malignant tumors. | negotiable |
| 93 | In vivo comparative studies of generic foreign antitumor drugs with commercial products: — study of antitumor activity in 1–2 tumors most sensitive to the prototype; — confirmation of the therapeutic dose range and dosing regimen; — comparative study of the efficacy of the substance and the dosage form | negotiable |
| 94 | Study of the photoinduced antitumor properties of drugs | negotiable |
| No. | Work / service | Unit price, RUB |
|---|---|---|
| 95 | Computer modeling of the obtained compounds for structure-activity relationships and further structural modification of the studied classes | negotiable |
| 96 | Creation of virtual libraries and preparation of training sets for these compounds based on the PASS Quasar system | negotiable |
| 97 | Literature and patent search for a given compound structure | negotiable |
| 98 | Custom synthesis of libraries of compounds with potential biological activity | negotiable |
| 99 | Production of scaled-up batches of pharmaceutical substances for further study | negotiable |
| 100 | Sample preparation of biological substances for further study by physicochemical methods | negotiable |
| 101 | Classical synthesis of peptides of up to 5 amino acid sequences | negotiable |
| 102 | solid-phase peptide synthesis by the FMOC method on the ResPep SLi automated synthesizer (Intavis, Germany) for sequences of up to 24 amino acids | negotiable |
| 104 | Purification of synthetic substances to the required level of purity | negotiable |
| 105 | Isolation and study of the chemical structure of compounds from plant raw materials | negotiable |
| 106 | Reversed-phase HPLC with mass spectrometric detection on the Agilent 1260 Series instrument | negotiable |
| 107 | High-resolution mass spectrometry on the SCIEX X500R QTOF tandem quadrupole time-of-flight mass spectrometer up to 45 kDa | negotiable |
| 108 | Recording of NMR spectra on 1H and 13C nuclei on the Spinsolve 80 ULTRA instrument | negotiable |
| 109 | Expert analysis of various options for the synthesis of organic compounds | negotiable |
Laboratory of Molecular Genetic Diagnostics and Personalized Medicine
| No. | Work / service | Unit price, RUB |
|---|---|---|
| 110 | Preparation of single-cell suspensions from solid tumors for flow cytometry (surgical material and paraffin blocks). | negotiable |
| 111 | Immunofluorescent phenotyping of cell cultures, solid and ascitic tumors, as well as normal tissues using a specified panel of markers. | negotiable |
| 112 | Statistical analysis and preparation of illustrative material for the results of immunofluorescent studies of tumor markers. | negotiable |
| 113 | Training under the program "Basic Principles and Specifics of Working with Tumor Cell Suspensions on a Flow Cytometer". | negotiable |
| No. | Work / service | Unit price, RUB |
|---|---|---|
| 114 | Development and validation of quality control and standardization methods for pharmaceutical substances, excipients, intermediates, and finished drugs | negotiable |
| 115 | Quality control of pharmaceutical substances, excipients, intermediates, and drugs (testing in accordance with the requirements of the current edition of the State Pharmacopoeia of the Russian Federation, the Pharmacopoeia of the EAEU, and the methods being developed) - visible mechanical inclusions, visual inspection: physical state (tablet, powder, amorphous mass, liquid, etc.), water (Karl Fischer), hydrogen ion index (pH), particle size distribution, dynamic viscosity, assay of the main substance, volume of injection solutions/ nominal volume/ extractable volume, dosage uniformity, determination of volatile substances and water, loss on drying, mass fraction of moisture, optical density, residue on ignition, refractive index, extraneous impurities/related compounds, clarity and turbidity of liquids, clarity and color, disintegration, dissolution, solubility, average mass/mass uniformity, specific rotation, purity and permissible limits of impurities) | negotiable |
| 116 | Performing the comparative dissolution kinetics test (CDKT) | negotiable |
| 117 | Study of the stability and shelf life of drugs in long-term, accelerated, and stress tests | negotiable |
| 118 | Transfer of quality control methods for pharmaceutical substances and drugs | negotiable |
| 119 | Development of regulatory documentation for the quality control of pharmaceutical substances and drugs, including Specifications | negotiable |
| 120 | Development of a marketing authorization dossier for a drug (Module 3 Quality) | negotiable |